Melbourne, Sep 25, 2008 AEST (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its United States-based sister company, Angioblast Systems Inc., was featured at the 2008 UBS Global Life Sciences Conference underway in New York.
Company founder Professor Silviu Itescu briefed international investors on the significant progress of Angioblast's clinical programs, including its ongoing Phase 2 trials for heart failure and heart attacks, plans to commence trials in vascular eye disorders such as diabetic retinopathy and macular degeneration, and new clinical directions in bone marrow transplantation.
Professor Itescu stated that this latest clinical opportunity may provide a fast-track path to early product commercialisation following the company's recent success in obtaining orphan drug designation to use its proprietary stem cells in cancer patients needing bone marrow transplantation.
The eighth annual UBS Global Life Sciences Conference is among the largest healthcare investor conferences in the world with around 3,500 attendees.
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
| ||
|
